Sildenafil Citrate
Product Images NDC 50436-3500

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 50436-3500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504363500)

The packaging label for Sildenafil Citrate by Unit Dose Services features a white background with black text. It lists the product name, strength of 50 mg, and identifies the unit dose form with one tablet per pouch, totaling 1,080 pouches per box. Additional details include Rx only status, storage instructions, and distributor information. The label also contains a barcode and a 2D matrix barcode.*

FDA Label Image

Chemical Structure (Sildenafil 01)

FDA Label Image

Figure 1 (Sildenafil 02)

A line graph comparing systolic blood pressure (mmHg) over 24 hours post-dose between Sildenafil 100 mg and placebo. The x-axis represents time in hours, and the y-axis shows changes in systolic blood pressure. Data points for each treatment group are connected, illustrating variations in blood pressure throughout the period.*

FDA Label Image

Figure 2 (Sildenafil 03)

A line graph depicting the change in systolic blood pressure (SBP) over time post-dose (in hours). It compares two treatment groups: Doxazosin with placebo and Doxazosin with Sildenafil 25 mg, showing trends in blood pressure changes across a 7-hour period.*

FDA Label Image

Figure 3 (Sildenafil 04)

Line graph showing the change in systolic blood pressure (SBP) in mmHg over time (hours) postdose for two groups: one receiving Doxazosin plus Placebo, and the other receiving Doxazosin plus Sildenafil 50 mg. The x-axis represents time in hours up to 8 hours, and the y-axis represents the change in SBP, ranging approximately from -50 to 40 mmHg. Data points are connected by lines with Doxazosin plus Placebo indicated by blue circles, and Doxazosin plus Sildenafil 50 mg by black diamonds.*

FDA Label Image

Figure 4 (Sildenafil 05)

A line graph comparing the effects of doxazosin combined with sildenafil 100 mg versus doxazosin combined with placebo over time after dosing (in hours). The y-axis measures a variable in mmHg, and the x-axis represents time from 0 to 8 hours post-dosing. The graph shows trends for both treatment groups across the time period.*

FDA Label Image

Figure 5 (Sildenafil 06)

A line graph showing plasma concentrations of Sildenafil Citrate over 24 hours post-dose. The x-axis represents time in hours, while the y-axis shows plasma concentration in ng/ml. The graph depicts concentration peaking shortly after dose, then declining steadily, based on data for a commercial tablet.*

FDA Label Image

Figure 6 (Sildenafil 07)

Two bar charts comparing the effect of Sildenafil Citrate and placebo on maintenance of erection by baseline score. The top chart shows percentage of patients at endpoint for Sildenafil Citrate across baseline scores 0 to 5, with increasing percentages at higher scores. The bottom chart shows the placebo effect with more varied percentages across baseline scores 0 to 5. Both charts use a legend with categories labeled 0 to 5.*

FDA Label Image

Figure 7 (Sildenafil 08)

A vertical bar chart depicting the percentage of patients reporting improvement across different treatment groups. The groups are placebo (24%, n=463), Sildenafil Citrate 25 mg (63%, n=214), Sildenafil Citrate 50 mg (74%, n=391), and Sildenafil Citrate 100 mg (82%, n=380). The chart shows increasing improvement percentages with higher Sildenafil Citrate doses.*

FDA Label Image

Greenstone Logo (Sildenafil 09)

FDA Label Image

Greenstone Logo (Sildenafil 10)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.